- Home
- IEP vs ADMA Comparison
IEP vs ADMA Comparison
Compare IEP & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IEP
- ADMA
- Stock Information
- Founded
- IEP 1987
- ADMA 2004
- Country
- IEP United States
- ADMA United States
- Employees
- IEP N/A
- ADMA N/A
- Industry
- IEP Auto Parts:O.E.M.
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IEP Consumer Discretionary
- ADMA Health Care
- Exchange
- IEP Nasdaq
- ADMA Nasdaq
- Market Cap
- IEP 4.7B
- ADMA 3.8B
- IPO Year
- IEP 1987
- ADMA N/A
- Fundamental
- Price
- IEP $10.43
- ADMA $15.84
- Analyst Decision
- IEP
- ADMA Strong Buy
- Analyst Count
- IEP 0
- ADMA 4
- Target Price
- IEP N/A
- ADMA $21.25
- AVG Volume (30 Days)
- IEP 580.0K
- ADMA 2.1M
- Earning Date
- IEP 02-26-2025
- ADMA 03-03-2025
- Dividend Yield
- IEP 33.54%
- ADMA N/A
- EPS Growth
- IEP N/A
- ADMA N/A
- EPS
- IEP N/A
- ADMA 0.28
- Revenue
- IEP $10,055,000,000.00
- ADMA $382,809,000.00
- Revenue This Year
- IEP N/A
- ADMA $66.90
- Revenue Next Year
- IEP N/A
- ADMA $13.76
- P/E Ratio
- IEP N/A
- ADMA $56.45
- Revenue Growth
- IEP N/A
- ADMA 63.39
- 52 Week Low
- IEP $8.53
- ADMA $5.08
- 52 Week High
- IEP $20.25
- ADMA $23.64
- Technical
- Relative Strength Index (RSI)
- IEP 68.24
- ADMA 39.58
- Support Level
- IEP $9.53
- ADMA $15.60
- Resistance Level
- IEP $10.05
- ADMA $16.67
- Average True Range (ATR)
- IEP 0.28
- ADMA 0.64
- MACD
- IEP 0.08
- ADMA 0.02
- Stochastic Oscillator
- IEP 77.54
- ADMA 24.44
About IEP Icahn Enterprises L.P.
Icahn Enterprises LP is a provider of diversified business services in the United States. The company operates its business through varied segments which include Investment, Automotive, Energy, Food Packaging, Real Estate, Pharma, and Home Fashion. Among these, the Energy segment derives the maximum revenue from the company. Geographically, it generates maximum revenue from the United States.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.